imatinib mesylate has been researched along with Neuroendocrine Tumors in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aghmesheh, M; Daly, D; Gandy, R; Goldstein, D; Symons, R | 1 |
| Ercaliskan, A; Eskazan, AE; Kabasakal, L; Kucukyurt, S; Yagiz Ozogul, Y | 1 |
| Coha, B; Holik, H; Kovač Peić, A; Novaković, S | 1 |
| Kato, S | 1 |
| Arioli, I; Bellone, M; Bongiovanni, L; Botti, L; Cancila, V; Chiodoni, C; Colombo, MP; Festinese, F; Jachetti, E; Parenza, M; Rigoni, A; Tardanico, R; Tripodo, C | 1 |
| Foukas, PG; Leontara, V; Machairas, A; Panayiotides, IG; Samaras, VD; Triantafyllou, K; Tsapralis, D; Tsompanidi, EM | 1 |
| Caplin, ME; Dhillon, AP; Hochhauser, D; Khan, K; Kostoula, V; Quaglia, A; Savage, K; Stubbs, M | 1 |
| Arnold, R; Barth, P; Blöcker, S; Göke, R; Hörsch, D; Lankat-Buttgereit, B | 1 |
3 review(s) available for imatinib mesylate and Neuroendocrine Tumors
| Article | Year |
|---|---|
Progress in the Treatment of Small Intestine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Duodenal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Neuroendocrine Tumors | 2023 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Gastroscopy; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms, Multiple Primary; Neuroendocrine Tumors; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2011 |
5 other study(ies) available for imatinib mesylate and Neuroendocrine Tumors
| Article | Year |
|---|---|
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.
Topics: Bone Marrow; Chemoradiotherapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radioisotopes; Sunitinib | 2020 |
Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Ascites; Cecal Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Neuroendocrine Tumors | 2017 |
Imatinib Spares cKit-Expressing Prostate Neuroendocrine Tumors, whereas Kills Seminal Vesicle Epithelial-Stromal Tumors by Targeting PDGFR-β.
Topics: Animals; Antineoplastic Agents; Biomarkers; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Mice; Mice, Transgenic; Neuroendocrine Tumors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor beta; Seminal Vesicles; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Expression of c-kit (CD117) in neuroendocrine tumours--a target for therapy?
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Binding Sites; Epitopes; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Neuroendocrine Tumors; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Neuroendocrine Tumors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Tumor Cells, Cultured | 2005 |